Pharma (Health) India Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 12-12-2024
- Paid Up Capital ₹ 1.85 M
as on 12-12-2024
- Company Age 29 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.32 M
as on 12-12-2024
- Revenue 4.15%
(FY 2022)
- Profit 187.50%
(FY 2022)
- Ebitda -267.22%
(FY 2022)
- Net Worth 5.53%
(FY 2022)
- Total Assets 24.00%
(FY 2022)
About Pharma (Health) India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.85 M.
The company currently has active open charges totaling ₹8.32 M.
Rachna Adlakha and Deepak Adlakha serve as directors at the Company.
- CIN/LLPIN
U24232HR1995PTC032675
- Company No.
032675
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationHaryana, Haryana
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Pharma (Health) India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Adlakha  | Managing Director | 16-May-1995 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rachna Adlakha | Director | 01-Jul-1995 | Current |
Financial Performance of Pharma (Health) India.
Pharma (Health) India Pvt Ltd, for the financial year ended 2022, experienced modest growth in revenue, with a 4.15% increase. The company also saw a substantial improvement in profitability, with a 187.5% increase in profit. The company's net worth moved up by a moderate rise of 5.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharma (Health) India?
In 2021, Pharma (Health) India had a promoter holding of 88.67% and a public holding of 11.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Of Commerce Creation Date: 22 Apr 2009 | ₹2.50 M | Open |
Punjab National Bank Creation Date: 13 Jun 1997 | ₹1.60 M | Open |
Punjab National Bank Creation Date: 02 Dec 1996 | ₹0.98 M | Open |
How Many Employees Work at Pharma (Health) India?
Unlock and access historical data on people associated with Pharma (Health) India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharma (Health) India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharma (Health) India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
